CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin
Patrick K. Reville(The University of Texas MD Anderson Cancer Center), Michael R. Green(Harvard University), Qunyan Yu(Sanofi (France)), Roberto Carrió(Sanofi (United States)), Laura Powers(Sanofi (France)), Ahyun Choi(Sanofi (France)), Mikielia Devonish(Sanofi (United States)), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Chaomei Shi(Sanofi (France)), Xubin Li(The University of Texas MD Anderson Cancer Center), Robin Meng(Sanofi (France)), Margot Cucchetti(Sanofi (France)), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Jing Jiao(China University of Geosciences), Virna Cortez‐Retamozo(Vrije Universiteit Brussel), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Jared Henderson(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), James Cao(Sanofi (Mexico)), Nathan Fowler(Repligen (United States)), Linghua Wang(The University of Texas MD Anderson Cancer Center), Ingrid Sassoon(Sanofi (France)), Nathan Pate(Sanofi (Mexico)), Dinesh S. Bangari(Sanofi (United States)), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Donald R. Shaffer(The University of Texas MD Anderson Cancer Center), Maria Agarwal(Sanofi (France)), Kelly Balko(Sanofi (France)), Katie Malley(Sanofi (Mexico)), Giovanni Abbadessa(Morristown Medical Center), Chizitara Okwuchi(The University of Texas MD Anderson Cancer Center), Julie-Ann Givigan(Sanofi (France)), Bing Liu(Central South University), Rui Wang(Dalian Ocean University), Xiangming Li(The University of Texas MD Anderson Cancer Center), Sukhvinder Sidhu(The University of Sydney), Xiaoyou Ying(Sanofi (France)), Tony Byers(The University of Texas MD Anderson Cancer Center), Elamaran Meibalan(Harvard University), Estela Rojas(The University of Texas MD Anderson Cancer Center), Enyu Dai(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k